RNA-biomarkers for diagnosis of prostate cancer

The present invention involves methods for the ex-vivo diagnosis of prostate cancer comprising the steps of i) providing a sample from a patient suspected of having prostate cancer and ii) analysing the expression level of at least one newly identified biomarker for prostate cancer in the sample, wherein, if the expression level of said biomarker is above a threshold value, the sample is designated as prostate cancer positive. Further, the invention involves stringent sample and method quality control criteria to ensure a reliable and specific method of diagnosing prostate cancer.